The Metabolic Landscape of RAS-Driven Cancers from Biology to Therapy

Overview

Journal Nat Cancer

Specialty Oncology

Date 2021 Apr 19

PMID 33870211

Citations 140

Authors

Suman Mukhopadhyay

Matthew G Vander Heiden

Frank McCormick

Affiliations

Soon will be listed here.

Abstract

Our understanding of how the RAS protein family, and in particular mutant KRAS promote metabolic dysregulation in cancer cells has advanced significantly over the last decade. In this Review, we discuss the metabolic reprogramming mediated by oncogenic RAS in cancer, and elucidating the underlying mechanisms could translate to novel therapeutic opportunities to target metabolic vulnerabilities in RAS-driven cancers.

Citing Articles

Metabolic reprogramming in cancer and senescence.

Zhang Y, Tang J, Jiang C, Yi H, Guang S, Yin G MedComm (2020). 2025; 6(3):e70055.

PMID: 40046406 PMC: 11879902. DOI: 10.1002/mco2.70055.

EMB-driven glioblastoma multiforme progression via the MCT4/GPX3 axis: therapeutic inhibition by Ganxintriol A.

Cheng B, Liu J, Gao L, Zhu Z, Yang Y, Liu S J Transl Med. 2025; 23(1):272.

PMID: 40038742 PMC: 11881305. DOI: 10.1186/s12967-025-06290-z.

Whole-exome sequencing identifies distinct genomic aberrations in eccrine porocarcinomas and poromas.

Puttonen M, Almusa H, Bohling T, Koljonen V, Sihto H Orphanet J Rare Dis. 2025; 20(1):70.

PMID: 39948683 PMC: 11823087. DOI: 10.1186/s13023-025-03586-7.

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives.

Takeda M, Yoshida S, Inoue T, Sekido Y, Hata T, Hamabe A Cancers (Basel). 2025; 17(3).

PMID: 39941797 PMC: 11816235. DOI: 10.3390/cancers17030428.

Fuel for thought: targeting metabolism in lung cancer.

Schneider J, Han S, Nabel C Transl Lung Cancer Res. 2025; 13(12):3692-3717.

PMID: 39830762 PMC: 11736591. DOI: 10.21037/tlcr-24-662.

References

Kelloff G, Hoffman J, Johnson B, Scher H, Siegel B, Cheng E . Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005; 11(8):2785-808. DOI: 10.1158/1078-0432.CCR-04-2626. View

van den Heuvel A, Jing J, Wooster R, Bachman K . Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth. Cancer Biol Ther. 2012; 13(12):1185-94. PMC: 3469476. DOI: 10.4161/cbt.21348. View

Sayin V, LeBoeuf S, Singh S, Davidson S, Biancur D, Guzelhan B . Activation of the NRF2 antioxidant program generates an imbalance in central carbon metabolism in cancer. Elife. 2017; 6. PMC: 5624783. DOI: 10.7554/eLife.28083. View

Bryant K, Stalnecker C, Zeitouni D, Klomp J, Peng S, Tikunov A . Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019; 25(4):628-640. PMC: 6484853. DOI: 10.1038/s41591-019-0368-8. View

Chio I, Tuveson D . ROS in Cancer: The Burning Question. Trends Mol Med. 2017; 23(5):411-429. PMC: 5462452. DOI: 10.1016/j.molmed.2017.03.004. View

Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D . RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011; 11(11):761-74. PMC: 3632399. DOI: 10.1038/nrc3106. View

Viale A, Pettazzoni P, Lyssiotis C, Ying H, Sanchez N, Marchesini M . Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014; 514(7524):628-32. PMC: 4376130. DOI: 10.1038/nature13611. View

Ramirez C, Hauser A, Vucic E, Bar-Sagi D . Plasma membrane V-ATPase controls oncogenic RAS-induced macropinocytosis. Nature. 2019; 576(7787):477-481. PMC: 7048194. DOI: 10.1038/s41586-019-1831-x. View

DeBerardinis R, Cheng T . Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2009; 29(3):313-24. PMC: 2809806. DOI: 10.1038/onc.2009.358. View

10.

White E . Exploiting the bad eating habits of Ras-driven cancers. Genes Dev. 2013; 27(19):2065-71. PMC: 3850091. DOI: 10.1101/gad.228122.113. View

11.

Amendola C, Mahaffey J, Parker S, Ahearn I, Chen W, Zhou M . KRAS4A directly regulates hexokinase 1. Nature. 2019; 576(7787):482-486. PMC: 6923592. DOI: 10.1038/s41586-019-1832-9. View

12.

Tate J, Bamford S, Jubb H, Sondka Z, Beare D, Bindal N . COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2018; 47(D1):D941-D947. PMC: 6323903. DOI: 10.1093/nar/gky1015. View

13.

Romero R, Sayin V, Davidson S, Bauer M, Singh S, LeBoeuf S . Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med. 2017; 23(11):1362-1368. PMC: 5677540. DOI: 10.1038/nm.4407. View

14.

Biancur D, Paulo J, Malachowska B, Del Rey M, Sousa C, Wang X . Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nat Commun. 2017; 8:15965. PMC: 5500878. DOI: 10.1038/ncomms15965. View

15.

Cichowski K, Jacks T . NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001; 104(4):593-604. DOI: 10.1016/s0092-8674(01)00245-8. View

16.

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

17.

Grossman R, Heath A, Ferretti V, Varmus H, Lowy D, Kibbe W . Toward a Shared Vision for Cancer Genomic Data. N Engl J Med. 2016; 375(12):1109-12. PMC: 6309165. DOI: 10.1056/NEJMp1607591. View

18.

Mukhopadhyay S, Saqcena M, Foster D . Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation. Oncoscience. 2015; 2(10):807-8. PMC: 4671930. DOI: 10.18632/oncoscience.253. View

19.

Best S, Ding S, Kersbergen A, Dong X, Song J, Xie Y . Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. Nat Commun. 2019; 10(1):4190. PMC: 6744438. DOI: 10.1038/s41467-019-12164-y. View

20.

Santana-Codina N, Roeth A, Zhang Y, Yang A, Mashadova O, Asara J . Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun. 2018; 9(1):4945. PMC: 6251888. DOI: 10.1038/s41467-018-07472-8. View